Tareq Al Baghdadi, MD
Medical Oncology · Ypsilanti, MINPI 1861515546
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $110,313 of the $115,672 with a category attached, or 95.4%. 21 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 28.3% of the total. Reporting peaked in 2022 at $31,668 and has fallen 59.3% since, to $12,885 in 2025. Among medical oncology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 93 payments — averaging $1243.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$33K
- AstraZeneca$27K
- Lilly USA, LLC$12K
- Genentech USA, Inc.$6K
- AbbVie$6K
- Gilead$5K
- plus $27K from 15 others
Across 161 payments — averaging $6827.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$583K
- Genentech, Inc.$127K
- E.r. Squibb & Sons, L.L.C.$106K
- Janssen Research & Development, LLC$69K
- Incyte Corporation$53K
- Pfizer$45K
- plus $117K from 6 others
What the payments were for
- Consulting fees$110,31395%
- Speaking & faculty fees$1,2601%
- Travel & lodging$3,0333%
- Food & beverage$1,0261%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 14 | $32,699 |
| AstraZeneca | 27 | $27,005 |
| Lilly USA, LLC | 4 | $12,000 |
| Genentech USA, Inc. | 5 | $6,444 |
| AbbVie | 12 | $5,927 |
| Gilead(2 entities) | 4 | $4,922 |
| Johnson & Johnson(2 entities) | 4 | $4,789 |
| Genmab U.S., Inc. | 3 | $3,505 |
| Incyte Corporation | 1 | $3,300 |
| Sobi, Inc | 2 | $3,219 |
| Morphosys, US Inc. | 1 | $2,655 |
| Bristol Myers Squibb | 3 | $1,976 |
| Janssen Scientific Affairs, LLC | 2 | $1,830 |
| Amgen | 2 | $1,551 |
| Karyopharm Therapeutics Inc. | 1 | $1,550 |
| Daiichi Sankyo Inc. | 3 | $1,110 |
| Astellas Pharma US Inc | 1 | $500 |
| Beigene, Ltd. | 1 | $450 |
| Athenex Pharmaceutical Division, LLC | 1 | $150 |
| Tempus AI, Inc | 1 | $73 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$115,672 in reported general payments places this provider in the 90th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 60 | $908,686 |
| JakafiRuxolitinib Phosphate | 49 | $844,671 |
| BrukinsaZanubrutinib | 65 | $711,404 |
| AlecensaAlectinib Hcl | 27 | $487,122 |
| ErleadaApalutamide | 33 | $478,685 |
| NubeqaDarolutamide | 25 | $296,150 |
| RetevmoSelpercatinib | 12 | $269,541 |
| TruqapCapivasertib | 11 | $241,870 |
| TazverikTazemetostat Hydrobromide | 12 | $239,201 |
| Lenalidomide | 16 | $217,628 |
| LynparzaOlaparib | 19 | $181,403 |
| VenclextaVenetoclax | 16 | $153,598 |
| JaypircaPirtobrutinib | 12 | $132,971 |
| Abiraterone Acetate | 98 | $130,542 |
| XareltoRivaroxaban | 38 | $37,955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,976 | $908,68660 claims |
| Incyte CorporationJakafi | $3,300 | $844,67149 claims |
| Johnson & JohnsonErleada, Xarelto | $4,789 | $516,64071 claims |
| Genentech USA, Inc.Alecensa | $6,444 | $487,12227 claims |
| AstraZenecaTruqap, Lynparza | $27,005 | $423,27330 claims |
| Lilly USA, LLCRetevmo, Jaypirca, Olanzapine | $12,000 | $403,01460 claims |
| AbbVieVenclexta, Creon | $5,927 | $161,05236 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,830 | $130,54298 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Ypsilanti
- Harry ErbaAnn Arbor$1.1M
- Philip PhilipDetroit$494K
- Shirish GadgeelDetroit$413K
- Patricia Lo RussoDetroit$322K
- Ammar SukariDetroit$273K
- Sami BrakeGrand Rapids$251K
- Frank WeinbergAnn Arbor$195K
- Wajahat KhanGrosse Pointe Woods$190K
- Charles SchifferDetroit$165K
- Francis WordenAnn Arbor$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.